Cytokine-mobilized peripheral blood progenitor cells

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• Peripheral blood progenitor cells (PBPCs) are increasingly used for transplantation, shifting from bone marrow to blood support.
• Mobilization strategies involving chemotherapy and/or cytokines are established but not yet optimized.
• Recombinant human cytokines like interleukin-3 (IL-3), granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF) are key agents.

Purpose of the Study:

• To review studies utilizing IL-3, G-CSF, and GM-CSF for PBPC mobilization.
• To evaluate the efficacy and safety of cytokine-based mobilization strategies.
• To determine optimal cytokine combinations or sequences for PBPC mobilization.

Main Methods:

• Review of clinical studies involving single-agent or combination/sequential use of IL-3, G-CSF, and GM-CSF.
• Analysis of data on PBPC mobilization, engraftment, and clinical outcomes.
• Assessment of patient tolerance and adverse events associated with cytokine therapy.

Main Results:

• Cytokine therapy alone is well-tolerated and effective for PBPC mobilization.
• Sequential administration of IL-3 and GM-CSF showed potential for enhancing PBPC mobilization.
• Specific cytokine regimens may influence the speed of platelet recovery post-transplantation.

Conclusions:

• Mobilization of PBPCs using cytokines alone is a recommended and safe approach.
• Sequential IL-3 and GM-CSF administration may be a beneficial strategy for autologous transplantation.
• Further research is needed to define optimal cytokine-based mobilization protocols for PBPCs.